Skip to content

Effect of Blueberries on Immunity

Immune Benefits of Blueberry Consumption in Overweight Older Men and Postmenopausal Women: A Randomized Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05534893
Acronym
Blueberry
Enrollment
52
Registered
2022-09-10
Start date
2022-10-12
Completion date
2023-09-12
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Response, Inflammation

Keywords

Blueberries, Immunity, Inflammation

Brief summary

This research study will test the effects of Blueberries on immune functions in overweight older men and postmenopausal women

Detailed description

This study will examine the effects of Blueberries on clinically relevant markers of immune function. Eligible and selected participants will be randomized to one of two groups at the baseline clinic visit. The Blueberry group participants will consume blueberries (2 packets of blueberry freeze-dried powder equivalent to 2 cups of fresh blueberries) added to the habitual diet and the Control group participants will abstain from blueberries (with instructions to limit the consumption of other berries and polyphenol rich foods) but otherwise continue their habitual diet. During the study, clinic visits will occur at 4-week intervals (baseline, weeks 4, 8 and 12) for a total of 4 visits at the Loma Linda University Nutrition Research Center. Blood samples taken at baseline and at week 12 will be assayed for changes in immune function and inflammatory markers.

Interventions

DIETARY_SUPPLEMENTBlueberry powder group

Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder

DIETARY_SUPPLEMENTPlacebo powder group

Participants in the placebo powder group will receive an isocaloric placebo powder

Sponsors

Loma Linda University
Lead SponsorOTHER
U.S. Highbush Blueberry Council
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The investigator, participant, care provider, outcomes assessor will not be aware of which participant is in which arm

Intervention model description

This will be a parallel, free-living, randomized controlled trial, where 52 overweight men and postmenopausal women will be randomized to receive either the freeze dried blueberries or a placebo powder

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Older men and post-menopausal women aged 50-70 year 2. Have BMI of 25-32 3. Able to commute to Loma Linda University 4. Consuming a typical American Diet low in polyphenols

Exclusion criteria

1. Intolerance or allergy to Blueberries 2. Regular intake of Blueberries and other berried (\>2 ounces/week) 3. Immune system insufficiency or disease 4. Using immune boosting supplements 5. Exposure to antibiotics and corticoids immediately prior to study 6. Uncontrolled chronic diseases and relevant psychiatric illness, including major depression 7. Flu vaccination and or Covid Vaccination less than 3 months ago from the start of the study

Design outcomes

Primary

MeasureTime frameDescription
changes in lymphocyte populationsbaseline to 12 weeksImmunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naïve and memory cells and B cells
changes in cytokine productionbaseline to 12 weeksPBMC cells will be separated from blood, activated and cultured using phytohemagglutinin (PHA). Inflammatory cytokine production will be measured in the resulting supernatant using ELISA
changes in natural killer (NK) cell activitybaseline to 12 weeksThe NK degranulation assay will be performed on blood samples. The test will be conducted using a modified flow cytometry method that measures the expression of CD107a
changes in serum inflammatory cytokine concentrationbaseline to 12 weeksChanges in the concentrations of the inflammatory cytokines will be performed on serum using enzyme-linked immunoassay (ELISA)
changes in complete blood count (CBC)baseline to 12 weekschanges in the complete blood count will be performed on whole blood with the use of an automated hematology analyzer at a certified clinical facility

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoan Sabate, DrPH

Loma Linda University

PRINCIPAL_INVESTIGATORSujatha Rajaram, PhD

Loma Linda University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026